Two-year data from the open-label extension show sustained ACR and MDA response rates for the TYK2 inhibitor in active psoriatic arthritis.
|Slideshows|July 12, 2018
Diet and Psoriatic Disease: 5 Questions Physicians Often Ask
New recommendations from the National Psoriasis Foundation offer answers. The express goal of these guidelines: to reduce disease severity through proper nutrition.
Advertisement
Reference1. Ford AR, Siegel M, Bagel J, et al. Dietary recommendations for adults with psoriasis or psoriatic arthritis from the Medical Board of the National Psoriasis Foundation: a systematic review. JAMA Dermatol. 2018 Jun 20. doi: 10.1001/jamadermatol.2018.1412. [Epub ahead of print]
Advertisement
Related to this article
Oberlin outlines what dermatologists should weigh, beyond APEX's radiographic data, when selecting a biologic for PsA.
In a large real-world PsA cohort, higher BMI reduced the odds of minimal disease activity, especially with TNF inhibitors other than infliximab.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
Baseline structural damage accounted for most of the variance in placebo-arm radiographic progression across 6 PsA trials.
Ruderman discusses how Northwestern's joint dermatology-rheumatology clinic shapes diagnosis and treatment of psoriatic disease.
Sonelokimab hit its primary ACR50 endpoint and all key secondary endpoints in biologic-naive patients with psoriatic arthritis in the phase 3 IZAR-1 trial.
Mease revisits the biggest PsA readouts from EULAR 2026: guselkumab, izokibep, GLP-1 combo therapy and more.
Advertisement
Advertisement